Appointment of acting CEO (6261Y)
05 March 2012 - 6:01PM
UK Regulatory
TIDMABH
RNS Number : 6261Y
Angel Biotechnology Holdings Plc
05 March 2012
05 March 2012
Angel Biotechnology Holdings plc
("Angel" or "the Company")
Appointment of Dr. Stewart White as Acting CEO
Angel Biotechnology Holdings plc, (AIM:ABH), the
biopharmaceutical contract manufacturer, is about to enter what the
Directors believe is an unprecedented period of growth. The
Cramlington facilty will shortly come on line for non-GMP
activities and we are working on a number of other projects. This
means that we must re-structure our staff around the needs of the
business and we expect to make a number of new appointments to
augment our existing senior team.
As part of this re-structuring activity the Board is pleased to
announce the appointment of Dr. Stewart White as Acting CEO
following the decision of the COO, Mr. Gordon Sherriff to leave the
Company. Dr. White was recruited into his present position as
Commercial Director with a view to his progression to becoming CEO
in due course. Stewart has made a significant impact on the
business since joining Angel in December 2011 and the Board has
every confidence in Stewart's ability to fulfill this new role and
for the appointment to be made permanent after a period of
evaluation.
Dr. Paul Harper, Executive Chairman, said: "Stewart has made an
excellent start in his role at Angel, bringing drive, focus and
leadership in his current role and more broadly across the
business. During Gordon Sherriff's period of absence, Stewart has
assumed a broad range of responsibilities alongside Lorna Peers,
our FD, and myself. The senior staff have responded magnificently
to the new challenges and greater responsibility supported by a
steady stream of new appointments at both Pentlands and
Cramlington."
For further information:
Angel Biotechnology Holdings plc
Lorna Peers, Finance Director +44 (0) 131 445 6077
Stewart White, Commercial Director www.angelbio.com
Grant Thornton, Corporate Finance
Colin Aaronson / Melanie Frean / Elliot Berg +44 (0) 20 7383
5100
Hybridan LLP (Broker)
Claire Noyce, Deepak Reddy +44 (0) 20 7947 4350
Media enquiries:
The Communications Portfolio Ltd
Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029
ariane.comstive@communications-portfolio.co.uk
Notes to Editors:
Angel Biotechnology Holdings plc is a full service contract
bio-manufacturing partner to biotechnology and pharmaceutical
companies worldwide. Angel specialises in advanced biologics
including biopharmaceutical proteins and cell therapies, such as
cellular vaccines and stem cells. At present, Angel's products are
principally used in pre-clinical studies and clinical trials with a
view to becoming the contract manufacturer of choice on a
continuing basis.
Drug development companies outsource their biopharmaceutical
manufacturing requirements to Angel to reduce their own capital
requirements and enable them to develop products more rapidly. In
addition, Angel provides complete regulatory services and
documentation to its customers while its manufacturing processes
adhere to the most stringent regulatory requirements. Products are
produced to current Good Manufacturing Practice (cGMP) standards as
required by the US Food and Drug Administration (FDA), and in
facilities that are certified to European standards by the
Medicines and Healthcare products Regulatory Agency (MHRA).
Its customers range from early-stage biotechnology companies
including ReNeuron plc and US-based Pathfinder Cell Therapy, to
established pharmaceutical companies such as Russian-based Materia
Medica Holdings.
Angel has two facilities: Pentlands Science Park near Edinburgh
where it employs 38 people, and a site in Cramlington, near
Newcastle-upon-Tyne, which is expected to be commissioned by the
end of Q1 2012, initially employing up to 10 people.
More information is available at www.angelbio.com .
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOALLFEEVAIFIIF
Angel Biotechnology (LSE:ABH)
Historical Stock Chart
From May 2024 to Jun 2024
Angel Biotechnology (LSE:ABH)
Historical Stock Chart
From Jun 2023 to Jun 2024